Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

arcellx inc - ACLX

ACLX

Close Chg Chg %
114.80 0.03 0.03%

Closed Market

114.83

+0.03 (0.03%)

Volume: 789.74K

Last Updated:

Apr 10, 2026, 4:00 PM EDT

Trade Now

Company Overview: arcellx inc - ACLX

ACLX Key Data

Open

$114.78

 Day Range

114.78 - 114.85

52 Week Range

47.86 - 114.93

 Market Cap

$6.71B

Shares Outstanding

58.48M

 Public Float

45.26M

Beta

0.25

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$4.05

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.23M

  

ACLX Performance

1 Week
 
 0.03%
 
1 Month
 
 0.36%
 
3 Months
 
 73.23%
 
1 Year
 
 94.08%
 
5 Years
 
 N/A
 

ACLX Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 17
Full Ratings ➔

About arcellx inc - ACLX

Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Redwood City MD.

ACLX At a Glance

Arcellx, Inc.
800 Bridge Parkway
Redwood City, California 94065
Phone 1-240-327-0630 Revenue 22.29M
Industry Biotechnology Net Income -228,934,000.00
Sector Health Technology Employees 209
Fiscal Year-end 12 / 2026
View SEC Filings

ACLX Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 164.728
Price to Book Ratio 9.387
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -13.282
Enterprise Value to Sales 146.85
Total Debt to Enterprise Value 0.016

ACLX Efficiency

Revenue/Employee 106,631.579
Income Per Employee -1,095,377.99
Receivables Turnover 6.191
Total Asset Turnover 0.034

ACLX Liquidity

Current Ratio 4.435
Quick Ratio 4.435
Cash Ratio 4.322

ACLX Profitability

Gross Margin 70.035
Operating Margin -1,135.614
Pretax Margin -1,026.945
Net Margin -1,027.255
Return on Assets -34.81
Return on Equity -53.418
Return on Total Capital -50.396
Return on Invested Capital -48.297

ACLX Capital Structure

Total Debt to Total Equity 12.904
Total Debt to Total Capital 11.429
Total Debt to Total Assets 8.596
Long-Term Debt to Equity 11.02
Long-Term Debt to Total Capital 9.76
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Arcellx Inc - ACLX

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
- 110.32M 107.94M 22.29M
Sales Growth
- - -2.16% -79.35%
-
Cost of Goods Sold (COGS) incl D&A
2.22M 2.04M 5.19M 6.68M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
2.22M 2.04M 5.19M 6.68M
Depreciation
2.22M 2.04M 5.19M 6.68M
Amortization of Intangibles
- - - -
-
COGS Growth
+113.64% -8.27% +154.31% +28.72%
Gross Income
(2.22M) 108.28M 102.75M 15.61M
Gross Income Growth
-113.64% +4,968.66% -5.11% -84.81%
Gross Profit Margin
- +98.15% +95.19% +70.03%
2022 2023 2024 2025 5-year trend
SG&A Expense
189.03M 198.16M 240.32M 268.69M
Research & Development
149.56M 133.85M 157.09M 157.61M
Other SG&A
39.48M 64.31M 83.23M 111.08M
SGA Growth
+195.47% +4.83% +21.28% +11.81%
Other Operating Expense
- - - -
-
Unusual Expense
- - - -
-
EBIT after Unusual Expense
(191.26M) (89.88M) (137.57M) (253.08M)
Non Operating Income/Expense
4.30M 23.70M 33.32M 24.22M
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- 1.72M 3.84M 1.03M
Interest Expense Growth
- - +123.37% -73.19%
-
Gross Interest Expense
- 1.72M 3.84M 1.03M
Interest Capitalized
- - - -
-
Pretax Income
(188.68M) (70.03M) (105.28M) (228.87M)
Pretax Income Growth
-190.41% +62.89% -50.34% -117.39%
Pretax Margin
- -63.48% -97.54% -1,026.95%
Income Tax
- 663.00K 2.07M 69.00K
Income Tax - Current - Domestic
- 663.00K 2.07M 69.00K
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(188.68M) (70.69M) (107.35M) (228.93M)
Minority Interest Expense
- - - -
-
Net Income
(188.68M) (70.69M) (107.35M) (228.93M)
Net Income Growth
-190.41% +62.53% -51.86% -113.26%
Net Margin Growth
- -64.08% -99.46% -1,027.25%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(188.68M) (70.69M) (107.35M) (228.93M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(188.68M) (70.69M) (107.35M) (228.93M)
EPS (Basic)
-4.2779 -1.4708 -2.004 -4.0659
EPS (Basic) Growth
-135.31% +65.62% -36.25% -102.89%
Basic Shares Outstanding
44.11M 48.06M 53.57M 56.31M
EPS (Diluted)
-4.2779 -1.4708 -2.004 -4.0659
EPS (Diluted) Growth
-135.31% +65.62% -36.25% -102.89%
Diluted Shares Outstanding
44.11M 48.06M 53.57M 56.31M
EBITDA
(189.03M) (87.84M) (132.38M) (246.41M)
EBITDA Growth
-195.47% +53.53% -50.71% -86.13%
EBITDA Margin
- -79.62% -122.65% -1,105.65%

Snapshot

Average Recommendation HOLD Average Target Price 112.846
Number of Ratings 17 Current Quarters Estimate -1.184
FY Report Date 06 / 2026 Current Year's Estimate -3.67
Last Quarter’s Earnings -1.113 Median PE on CY Estimate N/A
Year Ago Earnings -4.082 Next Fiscal Year Estimate -1.707
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 10 10 17 14
Mean Estimate -1.18 -1.07 -3.67 -1.71
High Estimates -0.96 -0.16 -0.49 1.95
Low Estimate -1.38 -1.50 -5.17 -4.62
Coefficient of Variance -11.63 -34.29 -31.11 -114.18

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 0 0 16
OVERWEIGHT 0 0 1
HOLD 17 17 2
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Hold Hold Buy

Insider Actions for Arcellx Inc - ACLX

Date Name Shares Transaction Value
Feb 20, 2026 Michelle Gilson CHIEF FINANCIAL OFFICER 44,302 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2026 Michelle Gilson CHIEF FINANCIAL OFFICER 50,662 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $67.73 per share 3,431,337.26
Feb 20, 2026 Michelle Gilson CHIEF FINANCIAL OFFICER 45,257 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $68.57 per share 3,103,272.49
Feb 20, 2026 Michelle Gilson CHIEF FINANCIAL OFFICER 45,157 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $69.38 per share 3,132,992.66
Jan 8, 2026 Christopher R. Heery CHIEF MEDICAL OFFICER 67,708 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 8, 2026 Rami Elghandour SEE REMARKS; Director 673,378 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 8, 2026 Christopher R. Heery CHIEF MEDICAL OFFICER 43,199 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 8, 2026 Christopher R. Heery CHIEF MEDICAL OFFICER 30,135 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 8, 2026 Christopher R. Heery CHIEF MEDICAL OFFICER 13,615 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 8, 2026 Christopher R. Heery CHIEF MEDICAL OFFICER 13,021 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 8, 2026 Christopher R. Heery CHIEF MEDICAL OFFICER N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 8, 2026 Christopher R. Heery CHIEF MEDICAL OFFICER 39,194 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 8, 2026 Michelle Gilson CHIEF FINANCIAL OFFICER 61,590 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 8, 2026 Michelle Gilson CHIEF FINANCIAL OFFICER N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 8, 2026 Michelle Gilson CHIEF FINANCIAL OFFICER 20,496 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 8, 2026 Rami Elghandour SEE REMARKS; Director 167,973 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 8, 2026 Rami Elghandour SEE REMARKS; Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 8, 2026 Rami Elghandour SEE REMARKS; Director 55,459 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 8, 2026 Rami Elghandour SEE REMARKS; Director 208,333 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 8, 2026 Rami Elghandour SEE REMARKS; Director 782,467 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Arcellx Inc in the News